The combination of BRAF, MEK and PD-1 inhibitors in BRAF-driven melanomas, have favoured cancer cell death and displayed promising results in early clinical trials for metastatic melanoma, supporting the concept that inhibiting the oncogenic signalling may reduce immune evasion and promote response to immune-checkpoint inhibitor therapy (ClinicalTrials.gov identifier: NCT02130466)86,87. This evidence concerns the gene BRAF and cancer.